Oral delivery of BCG Moreau Rio de Janeiro gives equivalent protection against tuberculosis but with reduced pathology compared to parenteral BCG Danish vaccination

Vaccine

Volumn 28, Issue 43, 2010, Pages 7109-7116

  Clark, Simon O ^a   Kelly, Dominic L F ^a   Badell, Edgar ^b   Castello Branco, Luiz Roberto ^c   Aldwell, Frank ^d   Winter, Nathalie ^d   Lewis, David J M ^e   Marsh, Philip D ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b INSTITUT PASTEUR   (France)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

BCG Moreau; Lipid formulation; Oral delivery

Indexed keywords

BCG MOREAU RIO DE JANEIRO VACCINE; BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENMARK; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; HEALTH CARE SYSTEM; HISTOPATHOLOGY; HUMAN; INFECTION PREVENTION; LUNG TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL RATE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; BCG VACCINE; GUINEA PIGS; INJECTIONS, SUBCUTANEOUS; LIPIDS; LUNG; MYCOBACTERIUM TUBERCULOSIS; SPLEEN; TUBERCULOSIS, PULMONARY;

EID: 77957336043     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.087     Document Type: Article

References (42)

1. Meya D.B., McAdam K.P. The TB pandemic: an old problem seeking new solutions. J Intern Med 2007, 261(April (4)):309-329.
2. Andersen P. TB vaccines: progress and problems. Trends Immunol 2001, 22(March (3)):160-168.
3. Aldwell F.E., Baird M.A., Fitzpatrick C.E., McLellan A.D., Cross M.L., Lambeth M.R., et al. Oral vaccination of mice with lipid-encapsulated Mycobacterium bovis BCG: anatomical sites of bacterial replication and immune activity. Immunol Cell Biol 2005, 83(October (5)):549-553.
4. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271(March (9)):698-702.
5. Demangel C., Garnier T., Rosenkrands I., Cole S.T. Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens. Infect Immun 2005, 73(April (4)):2190-2196.
6. Behr M.A. BCG-different strains, different vaccines?. Lancet Infect Dis 2002, 2(February (2)):86-92.
7. Comstock G.W. Field trials of tuberculosis vaccines: how could we have done them better?. Control Clin Trials 1994, 15(August (4)):247-276.
8. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346(November (8986)):1339-1345.
9. Ly L.H., McMurray D.N. Tuberculosis: vaccines in the pipeline. Expert Rev Vaccines 2008 Jul, 7(5):635-650.
10. Badell E., Nicolle F., Clark S., Majlessi L., Boudou F., Martino A., et al. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells. Vaccine 2009 Jan 1, 27(1):28-37.
11. Baumann U. Mucosal vaccination against bacterial respiratory infections. Expert Rev Vaccines 2008, 7(October (8)):1257-1276.
12. Vipond J., Cross M.L., Lambeth M.R., Clark S., Aldwell F.E., Williams A. Immunogenicity of orally-delivered lipid-formulated BCG vaccines and protection against Mycobacterium tuberculosis infection. Microbes Infect 2008, 10(November-December (14-15)):1577-1581.
13. Williams A., Hatch G.J., Clark S.O., Gooch K.E., Hatch K.A., Hall G.A., et al. Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 2005, 85(January-March (1-2)):29-38.
14. Benevolo-de-Andrade T.C., Monteiro-Maia R., Cosgrove C., Castello-Branco L.R. BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis-review. Mem Inst Oswaldo Cruz 2005, 100(August (5)):459-465.
15. Aldwell F.E., Tucker I.G., de Lisle G.W., Buddle B.M. Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice. Infect Immun 2003, 71(January (1)):101-108.
16. Cross M.L., Henderson R.J., Lambeth M.R., Buddle B.M., Aldwell F.E. Lipid-formulated BCG as an oral-bait vaccine for tuberculosis: vaccine stability, efficacy, and palatability to brushtail possums (Trichosurus vulpecula) in New Zealand. J Wildl Dis 2009, 45(July (3)):754-765.
17. Gheorghiu M., Lagrange P.H., Fillastre C. The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine. J Biol Stand 1988, 16(January (1)):15-26.
18. Cross M.L., Lambeth M.R., Aldwell F.E. An oral Mycobacterium bovis BCG vaccine for wildlife produced in the absence of animal-derived reagents. Clin Vaccine Immunol 2009, 16(September (9)):1378-1380.
19. Williams A., Davies A., Marsh P.D., Chambers M.A., Hewinson R.G. Comparison of the protective efficacy of bacille Calmette-Guerin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis. Clin Infect Dis 2000, 30(June (Suppl.) (3)):S299-301.
20. Chambers M.A., Williams A., Gavier-Widen D., Whelan A., Hall G., Marsh P.D., et al. Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin. Infect Immun 2000, 68(December (12)):7094-7099.
21. Lever M.S., Williams A., Bennett A.M. Survival of mycobacterial species in aerosols generated from artificial saliva. Lett Appl Microbiol 2000, 31(September (3)):238-241.
22. Chambers M.A., Williams A., Gavier-Widen D., Whelan A., Hughes C., Hall G., et al. A guinea pig model of low-dose Mycobacterium bovis aerogenic infection. Vet Microbiol 2001, 80(June (3)):213-226.
23. Wiegeshaus E.H., McMurray D.N., Grover A.A., Harding G.E., Smith D.W. Host-parasite relationships in experimental airborne tuberculosis. 3. Relevance of microbial enumeration to acquired resistance in guinea pigs. Am Rev Respir Dis 1970, 102(September (3)):422-429.
24. Williams A., James B.W., Bacon J., Hatch K.A., Hatch G.J., Hall G.A., et al. An assay to compare the infectivity of Mycobacterium tuberculosis isolates based on aerosol infection of guinea pigs and assessment of bacteriology. Tuberculosis (Edinb) 2005, 85(May (3)):177-184.
25. Yuki Y., Kiyono H. Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines 2009, 8(August 8):1083-1097.
26. Chen L., Wang J., Zganiacz A., Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect Immun 2004, 72(January (1)):238-246.
27. Giri P.K., Verma I., Khuller G.K. Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J Infect 2006, 53(November (5)):350-356.
28. Liu J., Tran V., Leung A.S., Alexander D.C., Zhu B. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin 2009, 5(February (2)):70-78.
29. Lotte A., Wasz-Hockert O., Poisson N., Dumitrescu N., Verron M., Couvet E. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res 1984, 21:107-193.
30. Behr M.A. Comparative genomics of BCG vaccines. Tuberculosis (Edinb) 2001, 81(1-2):165-168.
31. Hayashi D., Takii T., Fujiwara N., Fujita Y., Yano I., Yamamoto S., et al. Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guerin (BCG) substrains. FEMS Immunol Med Microbiol 2009, 56(July (2)):116-128.
32. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis. Vaccine 2009, 27(January (3)):441-445.
33. Ritz N., Hanekom W.A., Robins-Browne R., Britton W.J., Curtis N. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev 2008 Aug, 32(5):821-841.
34. Williams A., Hall Y., Orme I.M. Evaluation of new vaccines for tuberculosis in the guinea pig model. Tuberculosis (Edinb) 2009, 89(November (6)):389-397.
35. Barletta R.G., Snapper B., Cirillo J.D., Connell N.D., Kim D.D., Jacobs W.R., et al. Recombinant BCG as a candidate oral vaccine vector. Res Microbiol 1990, 141(September-October (7-8)):931-939.
36. Bastos R.G., Borsuk S., Seixas F.K., Dellagostin O.A. Recombinant Mycobacterium bovis BCG. Vaccine 2009 Nov 5, 27(47):6495-6503.
37. Capinos Scherer C.F., Endsley J.J., de Aguiar J.B., Jacobs W.R., Larsen M.H., Palmer M.V., et al. Evaluation of granulysin and perforin as candidate biomarkers for protection following vaccination with Mycobacterium bovis BCG or M. bovisDeltaRD1. Transbound Emerg Dis 2009, 56(August (6-7)):228-239.
38. Cayabyab M.J., Korioth-Schmitz B., Sun Y., Carville A., Balachandran H., Miura A., et al. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol 2009, 83(June (11)):5505-5513.
39. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005, 115(September (9)):2472-2479.
40. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000, 97(December (25)):13853-13858.
41. Pym A.S., Brodin P., Majlessi L., Brosch R., Demangel C., Williams A., et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003, 9(May (5)):533-539.
42. Brewer T.F. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000, 31(September (Suppl.) (3)):S64-S67.